CI
VRTX icon

Corient IA’s Vertex Pharmaceuticals VRTX Stock Holding History

Corient IA’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Sell
440
-60
-12% -$28K 0.18% 203
2025
Q4 		$227K Buy
+500
New +$216K 0.21% 188
2025
Q3 		– Sell
-600
Closed -$267K – 284
2025
Q2 		$267K Sell
600
-100
-14% -$46.1K 0.16% 240
2025
Q1 		$339K Buy
+700
New +$326K 0.24% 175

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Corient IA's VRTX Position: Q1 2026 in Review

Corient IA reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, selling an estimated $28K and leaving 440 shares worth $196K. The position accounts for 0.18% of the portfolio, ranked #203.

Corient IA first reported a position in VRTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $339K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Corient IA held 440 shares of Vertex Pharmaceuticals worth $196K as of Q1 2026.
  • Corient IA sold 60 Vertex Pharmaceuticals shares in Q1 2026, an estimated $28K.
  • Vertex Pharmaceuticals made up 0.18% of Corient IA's portfolio in Q1 2026, its #203 holding.
  • Corient IA first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Corient IA's Vertex Pharmaceuticals position peaked at $339K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Corient IA's 13F filing for Q1 2026, filed 14 May 2026.